Search

Roche Holding AG

Aperta

SettoreSettore sanitario

295.4 -1.86

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

291

Massimo

302.2

Metriche Chiave

By Trading Economics

Entrata

6.3B

Vendite

31B

P/E

Media del settore

29.748

63.778

Rendimento da dividendi

3.1

Margine di Profitto

20.347

Dipendenti

103,249

EBITDA

11B

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.10%

2.39%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

233B

Apertura precedente

297.26

Chiusura precedente

295.4

Notizie sul Sentiment di mercato

By Acuity

48%

52%

176 / 386 Classifica in Healthcare

Roche Holding AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 mar 2025, 09:23 UTC

I principali Market Mover

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

30 gen 2025, 09:36 UTC

Utili

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

30 gen 2025, 06:32 UTC

Utili

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

26 nov 2024, 15:27 UTC

Acquisizioni, Fusioni, Takeovers

Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion

31 mar 2025, 09:31 UTC

Azioni calde

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

13 mar 2025, 07:46 UTC

Discorsi di Mercato

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

12 mar 2025, 16:34 UTC

Notizie principali

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12 mar 2025, 08:51 UTC

Discorsi di Mercato

Roche's Multiple-Sclerosis Drug Sales Potential Fuels Rating Upgrade -- Market Talk

12 mar 2025, 08:18 UTC

Discorsi di Mercato

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

13 feb 2025, 11:43 UTC

Discorsi di Mercato

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

30 gen 2025, 07:56 UTC

Discorsi di Mercato
Utili

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

30 gen 2025, 06:04 UTC

Utili

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

30 gen 2025, 06:04 UTC

Utili

Roche Expects 2025 Sales Increase in Mid Single Digit Range at Constant Currency

30 gen 2025, 06:04 UTC

Utili

Roche Issues 2025 View

30 gen 2025, 06:03 UTC

Utili

Roche Raises Dividend to CHF9.70 Vs CHF9.60

30 gen 2025, 06:03 UTC

Utili

Roche 2024 Core Operating Profit CHF20.82B

30 gen 2025, 06:03 UTC

Utili

Roche 2024 Net Pft CHF9.19B

30 gen 2025, 06:02 UTC

Utili

Analysts Saw 2024 Core EPS at CHF18.59

30 gen 2025, 06:02 UTC

Utili

Roche 2024 Core EPS CHF18.80

30 gen 2025, 06:02 UTC

Utili

Roche 2024 Sales EUR60.50B

30 gen 2025, 06:02 UTC

Utili

Analysts Saw Roche 2024 Revenue at CHF60.41B

30 gen 2025, 06:01 UTC

Utili

Roche 2024 Sales CHFB

28 gen 2025, 10:30 UTC

Notizie principali

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

28 gen 2025, 07:24 UTC

Discorsi di Mercato

Roche's Breast Cancer Drug Extends Life of Patients -- Market Talk

15 gen 2025, 10:22 UTC

Discorsi di Mercato

Swiss Companies Pay Record Level of Dividends as Buybacks Fall -- Market Talk

8 gen 2025, 06:15 UTC

Acquisizioni, Fusioni, Takeovers

Roche: 66.11% of Poseida's Shares Were Validly Tendered in Offer

8 gen 2025, 06:12 UTC

Acquisizioni, Fusioni, Takeovers

Roche Intends to Complete Acquisition of Poseida Therapeutics Later Wednesday

16 dic 2024, 22:03 UTC

Notizie principali

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

13 dic 2024, 16:36 UTC

Discorsi di Mercato

Swiss Equities an Overweight Pick Next Year -- Market Talk

26 nov 2024, 16:10 UTC

Acquisizioni, Fusioni, Takeovers

Why This Gene-Therapy Company's Stock Is Rising 228% -- Barrons.com

Roche Holding AG Previsione

Sentiment

By Acuity

176 / 386 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.